Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2025
Reporting Period: Event-based report regarding a clinical trial milestone.
Key Financial Metrics
This filing is an Item 8.01 "Other Events" report and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Milestones
The Company announced a significant milestone in its Phase 2 clinical trial for Ropidoxuridine, a treatment for glioblastoma:
- Enrollment Status: Achieved 25% enrollment in the initial randomized portion of the trial.
- Trial Design:
- Initial randomization of 40 patients into two dose levels: 20 patients at 1,200 mg/day and 20 patients at 960 mg/day to determine the optimal dose.
- Upon identifying the optimal dose, 14 additional patients will be enrolled to reach statistical significance.
- Target Population: Patients with IDH wild-type, methylation negative glioblastoma (the most aggressive form of brain tumors).
- Clinical Context: Current standard of care for this cohort is radiation only, with less than 50% survival beyond 12 months post-diagnosis.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements regarding future results, strategy, and plans. These are based on management's current opinions and estimates and are subject to risks and uncertainties.
Risks and Contingencies:
- Actual results may differ materially from those expressed due to known and unknown risks.
- The Company undertakes no obligation to update forward-looking statements except as required by law.
- Information in this report is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed trial protocols and safety data.
- Review the Company's most recent periodic reports (10-K or 10-Q) for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor future filings for updates on the optimal dose selection and the enrollment of the additional 14 patients.
- Assess the competitive landscape for glioblastoma treatments and the specific survival benchmarks for historical controls mentioned.